chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Treatment of COVID-19; Treatment of COVID-19; Interchange of vaccine products; This is a spontaneous report received from contactable reporter(s) (Physician). The reporter is the patient.  A 75-year-old male patient received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), on 08Oct2022 as dose 5 (booster), single (Lot number: Gh9703) at the age of 75 years, in left arm for covid-19 immunisation; elasomeran (MODERNA COVID-19 VACCINE), on 29Dec2020 as dose 1, single (Lot number: 025j2da), in left arm, on 26Jan2021 as dose 2, single (Lot number: 029k20a), in left arm, on 22Oct2021 as dose 3 (booster), single (Lot number: 012f21a), in left arm and on 15Apr2022 as dose 4 (booster), single (Lot number: 002m21a), in left arm for covid-19 immunisation. The patient's relevant medical history included: "Hypertension" (unspecified if ongoing); "Chronic rhinitis" (unspecified if ongoing); "GERD" (unspecified if ongoing); "Hyperlipidemia" (unspecified if ongoing); "Lumbar spinal stenosis" (unspecified if ongoing). The patient's concomitant medications were not reported. The following information was reported: INTERCHANGE OF VACCINE PRODUCTS (medically significant) with onset 08Oct2022, outcome "unknown"; DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant) all with onset Feb2023, outcome "unknown" and all described as "Treatment of COVID-19". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (12Feb2023) Positive; (12Feb2023) Negative; (13Feb2023) Positive; (16Feb2023) Negative; (17Feb2023) Negative; (18Feb2023) Negative; (20Feb2023) Positive. Therapeutic measures were taken as a result of drug ineffective, covid-19. The patient received PF-07321332, ritonavir (PAXLOVID), from 12Feb2023 (Lot number: Unknown) to 17Feb2023 for covid-19 treatment.; Sender's Comments: The efficacy of a vaccine varies from patient to patient and may be influenced by multiple factors, including the inherent disease condition, concurrent medical conditions, and concomitant medications; however, a contributory role of BNT162B2, BNT162B2 OMI BA.4-5 to the reported events cannot  be excluded.  Case will be reassessed if additional information is received
Low grade fever Headache Muscle Aches Exhaustion - slept for more than 24 hours Lack of appetite
Client received extra dose of hep A vaccine. No adverse effects noted after wait time of 15 minutes.
5 minutes post-injection: slightly itchy scalp.  Gone 20 minutes later. 15 minutes post-injection: slightly itchy under chin, on neck and forearms.  No rash.  Gone 1 hour later. 5 hours post-injection: fatigue and nausea that came in waves.  Gone 24 hours later.
Patient was counseled before vaccine. Patient had not previously had any reaction to any other vaccine. Patient was nervous as it had been years since receiving a vaccine. Patient received vaccine and felt okay right afterwards. Was instructed to wait 15 minutes. As patient was in observation area talking with attendant he passed out. He hit the floor and had a seizure that lasted 1 minute. Pharmacist and store manager responded and 911 was called. Patient came to but kept going in a out of consciousness. While waiting on EMS a cold rag was placed on his neck and it seemed to help. EMS arrived and patient has low blood pressure and fast pulse. Blood sugar was normal. Patient declined ambulance ride to hospital . Patient parent picked him up. Store manager filled out an accident report.
Severe muscle and joint pain, incapacitated, unable to do or complete any function other than up to bathroom, severe headache with flashing lights and shapes. Symptoms lasted 36 hours.
All over body itchiness. I believe itching started in the evening. Eventually only itching on neck and a rash has developed. I?ve started putting cortisone cream on it but am not sure if it?s helping.
Immediately after shot: Weakness/Dizziness  Tingle and swelling in cheeks Cheeks felt warm to the touch Tingly, itchy and swelling on tongue
fever, chills, headache, - lasted about 1 1/2 days - similar to flu but without nausea.
Warm to touch, pain and swelling at injection site of right upper thigh. Treated with Ice and Tylenol.
Information has been received from a medical assistant concerning an 80 year old female patient with sulfa and LIPITOR allergy and a history of chemotherapy and radiotherapy in February 2010, who on 26-AUG-2009, was vaccinated SQ with a dose of ZOSTAVAX (Merck) (Lot# not reported). The medical assistant reported that on 21-AUG-2010, the patient developed severe shingles on her stomach and back after receiving ZOSTAVAX (Merck). The blisters were painful to the touch and she had the pain from neck to back. No lab tests were performed. The patient sought unspecified medical attention. At the time of the report, the patient had not recovered. Follow-up information was received which reported that the physician was very upset, because she saw the patient and the patient had still not recovered, the patient was seeing a pain management specialist. The physician has asked for follow-up from the safety department and from the medical information department. The physician also stated that the patient on unspecified date experienced post herpetic neuralgia (PHN), with severe pain (pins and needle-type pain) and the rash had healed. At the time of the report the patient's outcome from post herpetic neuralgia (PHN) was unknown. Additional information has been requested.
Nauseous; Dizzy Exhausted Couldn't stand upright because so weak Sweating Joint pain Headache Muscle pain  Symptoms lasted for weeks. Body hurt everywhere. The pain was intense. The fatigue continued a long time -- months.  Felt like a horrible fibromyalgia flare that started within hours of getting the second vaccine from Moderna.
Patient is a 51 yr old male with a PMHx significant for HTN, HLD, and bilateral uveitis who presented to ED after testing positive for COVID19 with worsening symptoms of chills, malaise, and shortness of breath.  Patient states he tested positive for COVID 14 days ago.  He continue to experience worsening symptoms so he called his PCP on 08/19 and was prescribed methylprednisone and a zpack.  Pt states he took it for 2 days however his symptoms persisted so pt presented to the ED at another hospital system\ on 08/22 where a chest xray showed COVID19 pneumonia.  Pt was prescribed Pulmicort and scheduled for convalescent plasma on 02/25. He was not admitted as he was noted to have a sat of 99% and was tolerating room air at the time.  He presented to receive his convalescent plasma today.  Patient states during his treatment he continued to be short of breath and his O2 sats dropped to the 90s.  Patient was brought to the ED via EMS.  On admission he was found to an elevated CRP and ferritin.  His white count was stable and he was afebrile.  His chest x-ray showed bibasilar patchy airspace opacities favoring infectious etiology.  Patient states he was vaccinated with Johnson & Johnson on 03/2121.   Patient is currently being admitted for further care.
4-5 days after shot patient saw a red dot, then it developed into blisters, she had itchiness and redness, no systemic side effects. Two weeks after shot she went to urgent care and they told her it was cellulitis and gave her a PEN VK shot and oral abx. Swelling has gone down since she started meds.
nasal congestion; cough; enlarged adenoids; This is a spontaneous report received from contactable reporter(s) (Other HCP)(nurse).  A 4 year-old male patient received pneumococcal 13-valent conjugate vaccine (diphtheria CRM197 protein)(PREVNAR 13) (Batch/Lot number: unknown) as dose 3, single, (Batch/Lot number: unknown) as dose 2, single and (Batch/Lot number: unknown) as dose 1, single for immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: NASAL CONGESTION (non-serious), outcome "unknown", described as "nasal congestion"; COUGH (non-serious), outcome "unknown", described as "cough"; ADENOIDAL HYPERTROPHY (non-serious), outcome "unknown", described as "enlarged adenoids". Relevant laboratory tests and procedures are available in the appropriate section.  Additional information: the patient was having nasal congestion over a prolonged period of time. He had 6 visits pertaining to the cough over 6 months. The nurse and physician ordered titers and 12 of the 13 serotypes were lower than normal  between 0.3 and 0.5.The office will vaccinate with PNEUMOVAX 23.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
ON 4/30/21 3 HOURS AFTER I HAD THE VACCINE  MY BLOOD PRESSURE WENT THROUGH THE ROOF.  MY HAND/ARMS WERE SHAKING, I WAS VERY SHORT OF BREATH AND COULD FEEL MY HEART BEATING OUT OF MY CHEST.   I WAS DRIVIN HALF WAY TO THE EMERGENCY ROOM  THEN SAT IN THE CAR FOR ABOUT 30 MINUTES TO CALM DOWN.    THE NIGHT OF 5/4/21 I WAS RELAXING AT HOME AND A LARGE DARK VEIN POPPED OUT IN MY LEFT CALF AND BECAME VERY SENSITIVE.  THE MORNING OF 5/5/21 I WENT AND SAW MY PRIMARY DR.   HE DIAGNOSED IT AS VERRUCOUS VIENS .  THE PAIN AND SENSITIVITY NEVER WENT AWAY.   5/10/21 MY LEGS BEGAN TO HAVE CONSTANT PINCHING  ON BOTH MY CALFS AND THIGHS.  5/12/21 THE PINCHING STARTED IN MY ARMS.  TODAY 5/14/21 I STILL HAVE PINCHING IN BOTH LEGS AND ARMS  IT IS NOT AS CONSTANT BUT STILL PRESENT.
Ended up in the ER last for a severe dull burning sensation at top of throat down esophagus to breast bone, radiating to jaw and shoulder. Pain had been building for three days and reached a crescendo, likely a delayed reaction to first injection of Moderna vaccine. Physicians thoroughly checked my heart functionality and sent me home. Two days later pain dissipated.
A 7 year old child was inadvertently given an adult Hep B dose.  Vital sign remain stable after the injection.
No additional AE; Drug use for unapproved indication; This spontaneous report was received from an other reporter referring to a female patient of unknown age from an article found by the reporter's daughter who was a nurse. The patient's concomitant medication, pertinent medical history and drug allergies/reactions were unknown by reporter. The patient's concurrent conditions included check pain that occurred from the trigeminal neuralgia shocks.     In July 2016, the patient was vaccinated with zoster vaccine live (ZOSTAVAX) (dose, strength, route, frequency, lot# and expiration date were not provided) for trigeminal neuralgia shocks (product use in unapproved indication). The patient's check pain that occurred from the trigeminal neuralgia shocks had resolved within a week and had no pains. No additional adverse event was reported.
Soreness at injection site, initially. Soreness, Redness, and Warmth increased over the next 5 days.
DPT shot it left her vulnerable to getting Whooping Cough which she did get; terrible allergic reaction; Infectious disease; This case was reported by a consumer via interactive digital media and described the occurrence of whooping cough in a female patient who received DTPa (DTPa vaccine) for prophylaxis.   On an unknown date, the patient received the 1st dose of DTPa vaccine. On an unknown date, unknown after receiving DTPa vaccine, the patient experienced whooping cough (serious criteria hospitalization and GSK medically significant), allergic reaction (serious criteria hospitalization) and infection (serious criteria hospitalization). The patient was treated with oxygen (Oxygen Therapy) and medication unknown (Intravenous Therapy (Nos)). On an unknown date, the outcome of the whooping cough, allergic reaction and infection were unknown.   It was unknown if the reporter considered the whooping cough, allergic reaction and infection to be related to DTPa vaccine.  Additional information was received as follows: Age at vaccination was not reported. This was a social media report. The patient got her 1st DPT shot and had a terrible allergic reaction which put her in the hospital. But by the patient not being able to get her DPT shot it left her vulnerable to getting Whooping Cough which she did get. She ended up in the hospital, in an oxygen tent in infectious disease where she was hooked up to so many IV's and machines.
12 hours after my 3rd shot I started feeling intense chills, body aches and a headache.; 36 hours later fever subsided but still had headache and aches; Now 3 days after receiving the booster I have a bad headache and still have joint pain.; 12 hours after my 3rd shot I started feeling intense chills, body aches and a headache.; 12 hours after my 3rd shot I started feeling intense chills, body aches and a headache.; I also had waves of nausea throughout the day; After around 18-20 hours these symptoms intensified and I began violently vomiting and had a fever of 101+ (highest was 102).; After around 18-20 hours these symptoms intensified and I began violently vomiting and had a fever of 101+ (highest was 102).; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 46 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administered in arm left, administration date 23Nov2021 17:00 (Lot number: FJ8757) at the age of 46 years as dose 3 (booster), single for covid-19 immunisation. The patient had no relevant medical history. There were no concomitant medications. Vaccination history included: Bnt162b2 (DOSE 2, SINGLE, Batch/Lot No: EN0176, Location of injection: Arm Left, Vaccine Administration Time: 09:00 AM), administration date: 29Apr2021, when the patient was 45 years old, for COVID-19 immunization; Bnt162b2 (DOSE 1, SINGLE, Batch/Lot No: ER8734, Location of injection: Arm Left, Vaccine Administration Time: 09:00 AM), administration date: 01Apr2021, when the patient was 45 years old, for COVID-19 immunization. The following information was reported: PAIN (non-serious), CHILLS (non-serious), HEADACHE (non-serious) all with onset Nov2021, outcome "recovering" and all described as "12 hours after my 3rd shot I started feeling intense chills, body aches and a headache."; PAIN (non-serious) with onset Nov2021, outcome "recovering", described as "36 hours later fever subsided but still had headache and aches"; ARTHRALGIA (non-serious) with onset Nov2021, outcome "recovering", described as "Now 3 days after receiving the booster I have a bad headache and still have joint pain."; NAUSEA (non-serious) with onset Nov2021, outcome "recovering", described as "I also had waves of nausea throughout the day"; VOMITING (non-serious), PYREXIA (non-serious) all with onset Nov2021, outcome "recovering" and all described as "After around 18-20 hours these symptoms intensified and I began violently vomiting and had a fever of 101+ (highest was 102).". Relevant laboratory tests and procedures are available in the appropriate section. Therapeutic measures were not taken as a result of pain, pain, arthralgia, chills, headache, nausea, vomiting, pyrexia.  Additional information: The patient did not receive any other vaccine in four weeks. There were no medications in two weeks. The patient did not had COVID prior vaccination. The patient tested COVID post vaccination. The patient had no known allergies.  Follow-up attempts are completed. No further information is expected.
Was accidentally given a Moderna booster (3rd dose, 0.25ml) shot that was 12 hours past its use by time; This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Was accidentally given a Moderna booster (3rd dose, 0.25ml) shot that was 12 hours past its use by time) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .25 milliliter. On an unknown date, the patient experienced EXPIRED PRODUCT ADMINISTERED (Was accidentally given a Moderna booster (3rd dose, 0.25ml) shot that was 12 hours past its use by time). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Was accidentally given a Moderna booster (3rd dose, 0.25ml) shot that was 12 hours past its use by time) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Concomitant medications details were not reported by the reporter. Treatment details were not reported by the reporter. It was reported that the patient was accidentally received a Moderna booster shot that was 12 hours past its use by time, total 24 hours since it was first punctured.
Extreme fatigue, some shortness of breath, soreness in injected arm, general feeling of malaise (felt like a dog!) for over 24 hours.  Rest, hydration, prayer.
first dosewas Moderna the second was Biontech; This spontaneous case was reported by a consumer and describes the occurrence of INTERCHANGE OF VACCINE PRODUCTS (first dosewas Moderna the second was Biontech) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced INTERCHANGE OF VACCINE PRODUCTS (first dosewas Moderna the second was Biontech). At the time of the report, INTERCHANGE OF VACCINE PRODUCTS (first dosewas Moderna the second was Biontech) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medication was provided. No treatment medication was provided.
Numbing of tongue, cannot see or hear for a minute, fainted.  He fell to ground and regain hearing and sight, and started to feel better.
I had diarrhea for 3months  nothing fixed it and it went away The second dose had the tingling around my mouth thought I was going in to anaphylaxis but subsided in about 5minutes
SEE LIST FOR  LIGHT HEADED , FACE FLUSHED 5/6 DAY OF  5/9  AWOKE 00:45 WITH SHORTNESS OF BREATH,  FACE PRICKLY feeling ,  CHILLS, oxigen  sat 99/%  lung clear,
Guillain-Barre suspected; Left arm hurt (at injection site) at the same time as weakness; This is a spontaneous report from a contactable other-health care professional reported for himself. A 59-year-old male patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE) dose 1 via an unspecified route of administration administered in left arm on 19Dec2020 (Lot Number: EL0140) as single dose for COVID-19 immunisation. Medical history included allergy to cashews. The patient did not receive any medications within 2 weeks of vaccination. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. The patient experienced lost use of legs and left arm hurt (at injection site) at the same time as weakness on 31Dec2020. Called ambulance, the patient went to ER. Evaluated for Stroke-like symptoms (negative). Guillain-Barre was suspected and EMG (Electromyography) confirmed it. The patient was hospitalized for event guillain-barre for 54 days. Event guillain-barre was also assessed as life-threatening and disability. The events resulted in doctor or other healthcare professional office/clinic visit and Emergency room visit. Treatment for events included IV-IG (Intravenous immunoglobulin); pneumothrombectomy (clots caused by IV-IG). The patient underwent nasal swab tests on 31Dec2020, 11Jan2021, 04Feb2021 and blood test on 24Mar2021, all were negative. The patient was not to have any more COVID vaccine per Neurology. The outcome of events was recovering.; Sender's Comments: Based on the information currently available, a possible contributory role of the suspect vaccine BNT162B2 in triggering the onset of Guillain-Barre cannot be excluded. The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to Regulatory Authorities, Ethics Committees and Investigators, as appropriate.
PT HAD EXTREME PAIN IN ENITRE BODY COULD, WAS DIFCULT TO WALK BUT IS BETTER NOW
difficulty breathing, headache, ocular headache, armpit swollen and injection site swollen, shortness of breath with exertion, fever
This case was reported by a physician via call center representative and described the occurrence of fever in a 58-year-old female patient who received SHINGRIX (batch number 4FS5N, expiry date 8th March 2021) for prophylaxis. On 24th October 2018, the patient received SHINGRIX. On 25th October 2018, 1 days after receiving SHINGRIX, the patient experienced fever and malaise. On 27th October 2018, the patient experienced pruritus. On 29th October 2018, the patient experienced rash. On an unknown date, the outcome of the fever and malaise were recovered/resolved and the outcome of the pruritus and rash were unknown. It was unknown if the reporter considered the fever, malaise, pruritus and rash to be related to SHINGRIX. Additional details were provided as follows: The patient received dose of SHINGRIX in the right deltoid. The patient developed a fever and malaise the day after receiving the SHINGRIX vaccine. Three days later, the patient developed itching in the left scapula area and the left chest area. Two days after the itching a rash developed. A few days ago, the patient developed bumps in the right inguinal region. The patient gave consent to be followed up.
client experienced syncope and seizure at approximately 9:55 am.  On site EMS was present at time of adverse event.  No known injury occurred, client was monitored/observed by EMS in private treatment area.  Client complained of feeling nauseous an appeared pale, but client alert and oriented.  EMS transferred client to stretcher from wheelchair, vitals were taken and stable. Client's spouse as notified.  At approximately 10:50 am 750cc fluid bolus started and 4mg Zofran administered at 10:55 am.  EMS continued to monitor/observe client's vitals.  Client signed release and departed facility with spouse in own transportation at approximately 12:02 pm.
Site: Bruising at Injection Site-Severe, Site: Itching at Injection Site-Severe, Site: Pain at Injection Site-Severe, Site: Redness at Injection Site-Severe, Site: Swelling at Injection Site-Severe, Systemic: Allergic: Anaphylaxis-Severe, Systemic: Allergic: Itch Generalized-Severe, Systemic: Allergic: Rash Generalized-Severe, Systemic: Body Aches Generalized-Severe, Systemic: Chills-Severe, Systemic: Flushed / Sweating-Severe, Additional Details: He called saying he had a lot of side effects. I recommended to go to urgent care or ER due to the generalized reaction.
shingles; This initial spontaneous report was received from a lawyer regarding a case in litigation and referred to a currently 58 years old female patient. No information was provided regarding medical history, concurrent conditions, or concomitant medications.   On an unknown date in 2017, the patient was vaccinated with zoster vaccine live (ZOSTAVAX) (lot number, expiration date, dose, dose number and route not specified) for long-term prevention of shingles and zoster-related conditions.  On an unspecified date, the patient experienced shingles. On an unspecified date, the patient was treated by a physician for shingles. The outcome of the event shingles was not reported. The reporter considered the event to be related to zoster vaccine live (ZOSTAVAX).  Additional information has been requested.
The first dose I had headaches 4 or 5 times a day.  From the day of the shot The second dose I had headaches.  Then one week later in the morning when I used the bathroom I fell into the wall when I tried to get up.  This is now been happening to me for 2 weeks.   I then called my Dr and was diagnosed with Vertigo.
Rash erythema, warmth, and itchiness to site of injection Narrative: erythema, warmth, and itchiness to site of injection